Martinez A.V.,Autonomous University of Nuevo Leon |
Flores M.G.,Hospital Universitario Dr Jose Eleuterio Gonzalez Ssa |
Candiani J.O.,Hospital Universitario Dr Jose Eleuterio Gonzalez Ssa
Dermatologia Cosmetica, Medica y Quirurgica | Year: 2012
Psoriasis is considered as a genetic, immunologic, inflammatory and chronic disease. It is characterized by the presence of erythematous, scaly plaques. It affects approximately 2% of the population. There are different therapeutic approaches and it is recommended to start with drugs that produce less side effects. The understanding of the immunologic basis of the disease has enabled the design of novel therapeutic agents. The new biologic agents provide selective therapeutic modalities that can minimize side effects. These agents are proteins that can be extracted from animal tissue or produced by recombinant dna technology and possess pharmacologic activity. They bind to specific antigens or cytokines preventing or reducing psoriasis manifestations. There are 3 different classes of biologic agents: monoclonal antibodies, fusion proteins and recombinant cytokines. Five of these agents are currently approved by the fda for their use in psoriasis: alefacept, etanercept, infliximab, adalimumab and ustekinumab. Clinical trials to study the security and efficacy of other agents such as secukinumab and briakinumab are being carried out In this article we review the mechanisms of action, indications, contraindications, doses and efficacy of every biologic agent used in the treatment of moderate to severe psoriasis.